China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has released its 2024 performance report, showing a robust 44% year-on-year (YOY) revenue growth to RMB 300 million (USD 41.3 million). This significant growth reflects the company’s expanding influence in the reproductive health sector.
Genetic Testing Division
The genetic testing division contributed RMB 160 million (USD 22 million) in sales, a 6% YOY increase. Preimplantation Genetic Testing (PGT) saw steady 15% growth, while the Expanded Carrier Screening (ECS) project experienced a remarkable 56% surge. These results highlight the increasing demand for advanced genetic screening services.
Embryo Lab Segment
The embryo lab segment recorded a significant 161% YOY increase in sales, reaching RMB 126 million (USD 17.3 million). Central to this success is the GERI time-lapse incubator, which features the world’s only humidity-compatible time-lapse imaging system. In 2024, China sales of this flagship product multiplied sixfold, with 42 units installed. Additionally, production costs are anticipated to decrease by over 30% with domestic registration expected in the first half of this year.-Fineline Info & Tech
